TRT for men: separating real benefits from TikTok hype

What's this video probably claiming?

A pharmacist-creator discussing TRT for men will almost certainly cover the standard talking points: testosterone naturally declines with age (roughly 1-2% per year after 30), low T causes fatigue, low libido, and muscle loss, and replacement therapy can fix all of that. The caption specifically promises coverage of how to diagnose low T, treatment options, safety, and side effects. Given the pharmacist background, the creator likely mentions getting a blood panel, references a threshold like 300 ng/dL as a cutoff for hypogonadism, and walks through delivery methods, probably testosterone cypionate or enanthate injections, topical gels, and maybe patches or pellets. The tone sounds balanced. That's encouraging. But even well-credentialed creators on TikTok tend to smooth over the parts that don't make for clean 60-second explanations, like the difference between symptomatic hypogonadism and age-related decline, or the real complexity of cardiovascular risk data.

What does the science actually show?

The clinical picture on TRT is more complicated than most TikTok videos let on. The landmark Testosterone Trials (Snyder et al., 2016, New England Journal of Medicine) enrolled 790 men aged 65 and older with low testosterone (below 275 ng/dL) and found modest improvements in sexual function, walking distance, and bone density, but no meaningful cognitive benefit and no dramatic body composition transformation. The 2023 TRAVERSE trial (Lincoff et al., New England Journal of Medicine) was a major development: it followed over 5,000 middle-aged and older men with hypogonadism and cardiovascular risk factors for about 33 months and found TRT was non-inferior to placebo for major cardiovascular events, largely putting to rest the 2010 Basaria et al. safety scare. That said, TRAVERSE also confirmed a higher rate of atrial fibrillation, pulmonary embolism, and acute kidney injury in the testosterone group. These are not rare enough to ignore. The benefits are real but incremental for most men.

Where does the social media noise diverge from clinical reality?

The biggest gap between TikTok TRT content and clinical reality is the threshold problem. Many creators, including pharmacist-influencers, treat any testosterone level under 300 ng/dL as a diagnosis requiring treatment. Clinical guidelines from the American Urological Association and the Endocrine Society are more specific: they require two morning fasting measurements below 300 ng/dL combined with symptoms to even consider treatment. A single afternoon blood draw, which is common in direct-to-consumer hormone clinics, can be artificially low due to diurnal variation. Total testosterone also tells an incomplete story. Free testosterone and sex hormone-binding globulin levels matter too. Then there's the fertility issue. TRT suppresses the hypothalamic-pituitary-gonadal axis, which reduces sperm production significantly. Liu et al. (2006, Journal of Clinical Endocrinology and Metabolism) documented oligospermia or azoospermia in a large proportion of men on exogenous testosterone. This side effect routinely gets underplayed in short-form content aimed at younger men who may still want children.

What should you actually know?

If you're watching a TRT video because you feel tired and low-energy, that's reasonable, but low testosterone is not the only or even the most common explanation for those symptoms. Sleep apnea, obesity, depression, and hypothyroidism all produce nearly identical symptom profiles and are far more prevalent than true hypogonadism. Get a proper workup before assuming your testosterone level is the problem. If TRT is genuinely appropriate, the delivery method matters more than most people think. Intramuscular injections of testosterone cypionate (typically 100-200 mg per week in clinical practice) produce higher peaks and troughs than gels or patches, which release more steadily. Pellets have a long half-life that makes dose adjustments difficult if problems arise. No delivery method is universally superior. The Endocrine Society's 2018 clinical practice guidelines (Bhasin et al., Journal of Clinical Endocrinology and Metabolism) remain the most rigorous framework for these decisions. Work with a provider who actually monitors hematocrit, PSA, and lipids during treatment.